semaglutide same as zepbound outperforms Ozempic and Wegovy in head-to-head weight loss study Zepbound vs Wegovy: A Comprehensive

Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents

Serious but Rare Side Effects: Severe liver injury (reported in less than 0.1% of patients) and kidney stones in some individuals

In addition, the use of Japanese-specific utility values where available and Japanese real-world claims data for key complication costs further supports the relevance of the analysis to the Japanese healthcare setting

This result was considered a statistically positive investigation, however the results did not reach the threshold to constitute a clinically meaningful study. When interpreting studies, both clinicians and scientists will opine as to whether the outcome of this study was clinically meaningful